Second Circuit says Takeda can’t dodge two antitrust suits

The US Court of Appeals for the Second Circuit has denied an appeal from Takeda Pharmaceuticals to shut down two antitrust suits related to its diabetes drug Actos.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Big Pharma

Novavax partners with Takeda to deliver COVID-19 vaccine in Japan

10 August 2020 US biotechnology company Novavax has signed a deal with Takeda Pharmaceuticals to develop, manufacture and market a COVID-19 vaccine in Japan, it was announced on Friday, August 7.

Asia

AstraZeneca and Takeda enter agreement to develop Parkinson’s disease drug

29 August 2017 AstraZeneca and Takeda have entered into an agreement to develop and commercialise MEDI1341, an alpha-synuclein antibody currently in development as a potential treatment for Parkinson’s disease.

More on this story

Big Pharma

Novavax partners with Takeda to deliver COVID-19 vaccine in Japan

10 August 2020 US biotechnology company Novavax has signed a deal with Takeda Pharmaceuticals to develop, manufacture and market a COVID-19 vaccine in Japan, it was announced on Friday, August 7.

Asia

AstraZeneca and Takeda enter agreement to develop Parkinson’s disease drug

More on this story

Big Pharma

Novavax partners with Takeda to deliver COVID-19 vaccine in Japan

10 August 2020 US biotechnology company Novavax has signed a deal with Takeda Pharmaceuticals to develop, manufacture and market a COVID-19 vaccine in Japan, it was announced on Friday, August 7.

Asia

AstraZeneca and Takeda enter agreement to develop Parkinson’s disease drug